Söndag 22 December | 04:50:47 Europe / Stockholm

Kalender

Tid*
2026-02-25 08:00 Bokslutskommuniké 2025
2025-10-29 08:00 Kvartalsrapport 2025-Q3
2025-08-27 08:00 Kvartalsrapport 2025-Q2
2025-05-20 N/A Årsstämma
2025-04-30 08:00 Kvartalsrapport 2025-Q1
2025-02-26 08:00 Bokslutskommuniké 2024
2024-12-06 - Extra Bolagsstämma 2024
2024-10-23 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning INIFY 0.00 NOK
2024-05-14 - Årsstämma
2024-04-24 - Kvartalsrapport 2024-Q1
2024-02-29 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning INIFY 0.00 NOK
2023-05-16 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-08-30 - Extra Bolagsstämma 2022
2022-08-17 - Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Inify Laboratories tillhandahåller cancerdiagnostik genom laboratorietjänster inom patologi. Bolaget använder ett digitalt, standardiserat arbetsflöde för svarstider och kvalitetssäkring, initialt inom prostata diagnostik. Kunderna består främst utav laboratorier och sjukhus. Inify Laboratories grundades år 2022 och har sitt huvudkontor i Stockholm, Sverige.
2024-12-09 12:05:01
STOCKHOLM - 9 December 2024 - Reference is made to the stock exchange
announcement made by Inify Laboratories AB (the "Company") on 15 November 2024,
regarding a proposed fully guaranteed share issue generating gross proceeds of
approximately SEK 150 million, and the extraordinary general meeting held 6
December 2024 which resolved to authorize the board of directors of the Company
to resolve on the issuance of new shares.

The board of directors has today resolved to launch the fully guaranteed private
placement of 30,000,000 new shares (the "Private Placement Shares") with gross
proceeds of the NOK equivalent of approximately SEK 135 million with a minimum
subscription per subscriber of the NOK equivalent of EUR 100,000 (the "Private
Placement"), directed pro-rata towards existing shareholders holding more than
400,000 shares in the Company (other than Avanza Bank AB) (the "Eligible
Shareholders"). The Private Placement will, subject to completion of the Private
Placement, and certain other conditions, be followed by a fully guaranteed
repair issue of the NOK equivalent of approximately SEK 15 million (the
"Subsequent Offering"), directed pro-rata towards all existing shareholders
other than the Eligible Shareholders, as further described below.

Only shareholders in the Company will be able to participate, on a pro-rata
basis, in the Private Placement and the Subsequent Offering, as applicable.
Shareholders will be able to maintain their pro-rata shareholding in the Company
after the Private Placement and the Subsequent Offering, as long as such
shareholders submit an application corresponding to their pro-rata shareholding
in the Company.

The net proceeds from the Private Placement and the Subsequent Offering will be
used to fund the Company's expansion into the United Kingdom and for general
corporate purposes.

The subscription price per share in the Private Placement and the Subsequent
Offering will be NOK 4.50.

Application period for Private Placement

The application period for the Private Placement commences today, 9 December
2024, and ends on 13 December at 16:30 hours CET (the "Private Placement
Application Period"). The Company may extend or shorten the Privat Placement
Application Period at any time and for any reason on short, or without, notice.
If the Private Placement Application Period is extended or shortened, the other
dates referred to herein might be changed accordingly.

Record date and application period for Subsequent Offering

The Subsequent Offering will, subject to applicable securities law, be directed
towards all existing shareholders in the Company other than the Eligible
Shareholders as of 13 December 2024 (as registered in Euronext Securities Oslo
(the "VPS") or Euroclear, as applicable, on 17 December 2024 (the "Record
Date")), who are not resident in a jurisdiction where such offering would be
unlawful or would (in jurisdictions other than Norway) require any prospectus,
filing, registration or similar action.

The Company will publish a national (Norwegian) prospectus in the beginning of
January 2025 and thereafter commence the two-week application period for the
Subsequent Offering (the "Subsequent Offering Application Period"). Shareholders
with shares registered with the VPS as of the Record Date will receive non
-transferable subscription rights at the start of the Subsequent Offering
Application Period. Shareholders with shares registered directly with Euroclear
as of the Record Date will not receive any subscription rights. Instead, such
shareholders will receive an application form which shall be used to apply for
subscription for shares in the Subsequent Offering.

The key dates for the Subsequent Offering are set out below:

· Last day of trading in the Company's shares including the right to
participate in Subsequent Offering: 13 December
· Ex-date: 16 December 2024
· Record date: 17 December 2024
· Subsequent Offering Application Period: on or around 9 January 2025 - 23
January 2025.

Settlement

The date for payment of the Private Placement and the Subsequent Offering is
expected to be on or about 14 February 2025 (the "Payment Date"). The new shares
in the Private Placement and the Subsequent Offering are expected to be
delivered on or about 17 February 2025, and turnaround time for registration of
the share capital increases relating to the Private Placement and the Subsequent
Offering with the Swedish Companies Registration Office ("SCRO"). The shares
allocated in the Private Placement and the Subsequent Offering will be tradable
on Euronext Growth Oslo when the new shares have been registered with the SCRO
and registered by Euroclear Sweden and VPS, respectively, expected on or about
17 February 2025.

Advisors

SpareBank 1 Markets AS ("SpareBank 1 Markets") has been appointed as financial
advisor in connection with the Private Placement and the Subsequent Offering.
Schjødt law firm acts as legal counsel to the Company.

For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com

###

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardized and AI
-supported workflow to optimize quality and response times, initially within
prostate. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to
sample preparation, to reporting by a pathologist. The report is assisted by our
own AI, proven in clinical studies to have world-leading accuracy. The complete
workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from
ContextVision(https://www.contextvision.com/), with 40 years of experience
within digital imaging for medical applications. It is listed on Euronext Growth
Oslo under the ticker
INIFY(https://live.euronext.com/en/product/equities/SE0017486103-MERK).

This information is subject to the disclosure requirements pursuant to section 5
-12 the Norwegian Securities Trading Act.

Important information

The release, announcement or distribution of this press release may, in certain
jurisdictions, be subject to restrictions. The recipients of this press release
in jurisdictions where this press release has been published or distributed
shall inform themselves of and follow such restrictions. The recipient of this
press release is responsible for using this press release, and the information
contained herein, in accordance with applicable rules in each jurisdiction. The
information in this press release does not contain or constitute an offer to
acquire, subscribe or otherwise trade in shares, subscription rights or other
securities in the Company in any jurisdiction. Any invitation to the persons
concerned to subscribe for shares in the Subsequent Offering will only be made
through the national (Norwegian) prospectus which the Company expects to publish
in the beginning of January 2025.

This press release does not identify or suggest, or purport to identify or
suggest, the risks (direct or indirect) that may be associated with an
investment in new shares. Any investment decision in connection with the Private
Placement and Subsequent Offering must be made on the basis of all publicly
available information relating to the Company and the Company's shares. Such
information has not been independently verified by SpareBank 1 Markets. The
information contained in this announcement is for background purposes only and
does not purport to be full or complete. No reliance may be placed for any
purpose on the information contained in this announcement or its accuracy or
completeness. SpareBank 1 Markets is acting for the Company in connection with
the transaction and no one else and will not be responsible to anyone other than
the Company for providing the protections afforded to its clients nor for giving
advice in relation to the transaction or any other matter referred to herein.

This press release does not constitute a recommendation concerning any
investor's option with respect to the Private Placement and Subsequent Offering.
Each investor or prospective investor should conduct his, her or its own
investigation, analysis and evaluation of the business and data described in
this announcement and publicly available information. The price and value of
securities can go down as well as up. Past performance is not a guide to future
performance.

The information contained in this press release is not intended for, and must
not be accessed by, or distributed or disseminated, directly or indirectly, in
whole or in part, to persons resident or physically present in the United States
of America (including its territories and possessions, any state of the United
States and the District of Columbia) (the "United States"), Australia, Canada,
Hong Kong, Japan, New Zealand, Singapore, South Africa, United Kingdom or any
other jurisdiction where such action is wholly or partially subject to legal
restrictions, or would require additional prospectuses, registration or other
measures than those required by Norwegian law. The information in the press
release does not constitute any offer regarding subscription rights, paid
subscribed shares or shares in the Company ("Securities") to any person in said
jurisdictions. The information in the press release may not be forwarded or
reproduced in such a manner that contravenes such restrictions or gives cause to
such requirements.

No securities have been or will be registered under the United States Securities
Act of 1933, as amended (the "Securities Act") or the securities legislation of
any state or other jurisdiction in the United States and may not be offered,
subscribed for, exercised, used, pledged, sold, resold, granted, delivered or
otherwise transferred, directly or indirectly, in or into the United States
except pursuant to an applicable exemption from, or in a transaction not subject
to, the registration requirements under the Securities Act and in compliance
with the securities legislation in the relevant state or any other jurisdiction
of the United States.

Within the European Economic Area ("EEA"), no public offering of Securities is
made in other countries than Sweden or Norway. In other member states of the EU,
such an offering of Securities may only be made in accordance with the
Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation"). In other
member states of the EEA which have implemented the Prospectus Regulation in its
national legislation, any offer of Securities may only be made in accordance
with an applicable exemption in the Prospectus Regulation and/or in accordance
with an applicable exemption under a relevant national implementation measure.

In the United Kingdom, this document and any other materials in relation to the
securities described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this document relates is
available only to, and will be engaged in only with, "qualified investors" who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of "investment professionals" in
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order")